Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines

Vanda Pharmaceuticals VPO-227 granted US FDA Orphan Drug Designation for the treatment of cholera

Peptilogics Presents Data Demonstrating Antimicrobial Activity Against Difficult to Treat Bacterial Pathogens of Engineered Peptide PLG0206

US FDA Approves Orkambi in Children with Cystic Fibrosis Ages 12 to <24 Months

Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine

EpiAxis Therapeutics and Peptilogics Enter Strategic Drug Discovery Partnership

Vicinitas Therapeutics Launches with USD 65m in Series A Financing

Endo Ventures signs development and distribution contract with Quoin Pharmaceuticals

ReCode Therapeutics Closes Series B Extension Financing Round

First Two Patients Dosed in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis

Health Canada Grants Marketing Authorization for Trikafta in Children with Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation

Cystic Fibrosis Foundation Invests USD 5m in Sionna Therapeutics to Develop New CFTR Modulator Therapy

Laurent Pharmaceuticals Starts Phase 3 Study with Once-a-Day Oral COVID-19 Antiviral Treatment Candidate in Hospitalized Moderate-to-Severe Patients

Cyclica Launches University of Toronto Spinout Perturba Therapeutics

Northwestern Medicine's study shows lung transplantation highly effective and successful in critically-ill COVID-19 patients